Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:37:38.851Z.
Calculation as of: 2026-10-06T19:37:38.851Z.
Quote observation: 2026-10-06T19:34:51.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a49bf55b95e7accb53c24ef9933cb867312288378507dab28e57e4bc75072383
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$23.15M
EBITDA Yield
N/A
TTM Avg
217.80%
3Y Avg
229.94%
5Y Avg
229.94%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InspireMD, Inc. (NSPR) | $24.44M | N/A | N/A | N/A | N/A |
| iTonic Holdings Ltd. (ITOC)vs › | $26.39M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.54M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.65M | N/A | 0.01% | 0.01% | 0.01% |
| Kyntra Bio, Inc. (KYNB)vs › | $24.05M | N/A | 1.43% | 1.43% | 1.43% |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.15M | N/A | 217.80% | 229.94% | 229.94% |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.70M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $27.73M | N/A | N/A | N/A | N/A |
| Rein Therapeutics Inc. (RNTX)vs › | $22.94M | N/A | N/A | N/A | N/A |
| OneMedNet Corporation (ONMD)vs › | $28.76M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
